Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice

Circulation

Volumn 97, Issue 8, 1998, Pages 780-785

  Shah, Prediman K ^a,d   Nilsson, Jan ^b   Kaul, Sanjay ^a   Fishbein, Michael C ^a   Ageland, Hans ^b   Hamsten, Anders ^c   Johansson, Jan ^c   Karpe, Frederick ^b   Cercek, Bojan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Pharmacia & Upjohn AB   (Sweden)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Apolipoproteins; Atherosclerosis; Hypercholesterolemia

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN E; CHOLESTEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; DISEASE CONTROL; DISEASE COURSE; DOSE RESPONSE; HEPATOMA CELL; HYPERCHOLESTEROLEMIA; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032478183     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.8.780     Document Type: Article

References (50)

1. Rhoads GG, Gulbrandsen CL, Kagan A, Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med. 1976;294:293-298.
2. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tomso Heart Study: high density lipoproteins and coronary heart disease: a prospective case control study. Lancet. 1977;1:965-968.
3. Gordon T, Castelli WP, Hjortland M, Kannel W, Dawber T. High density lipoprotein as a protective factor against coronary heart disease. Am J Med. 1977;62:707-714.
4. Gordon DJ, Rifkind BM, High-density lipoprotein: the clinical implications of recent studies. N Engl J Med. 1989;19:1311-1316.
5. Gordon DJ, Probstfeld JL, Garrison RJ, Neaten JD, Castelli WP, Knoke JD, Jacobs JR Jr. Bangdiwala S, Tyroler A. High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
6. Tall A. Plasma high density lipoproteins: metabolism and relationship to atherogenesis J Clin Invest. 1990;86:379-384.
7. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high-density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234-1241.
8. Rubin EM Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by apolipoprotein A-I. Nature. 1991;353:265.
9. Plump AS, Scott CJ, BreslowJL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1994;91:9607-9611.
10. Pastzy C, Maeda N, Vesrtuyft JG, Rubin EM., Apolipoprotein A-I transgene corrects apolipoprotein E deficiency induced atherosclerosis in mice. J Clin Invest. 1994;94:899-903.
11. Miyazaka Miyazaki A, Sakuma S, Morikawa W, Takiue T, Miake F, Terano T. Sakai M, Hakamata H, Sakamoto Y, Natio M. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-led rabbits. Arteriosler Thromb Vasc Biol. 1995;15:1882-1888.
12. Franceschini C, Sirtori CR, Capurso A, Weisgraber KH, Mahley RW. A-I Milano apoprtein: decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980;66:892-900.
13. Weisgraber KH, Bersot TP, Mahley RW, Franceschini G, Magani D, Sirtori CR. Isolation and characterization of A cysteine-containing varient of the apoprotein A-1 from high density lipoprotein. J Clin Invest., 1980;66:901-907.
14. milano apoprotein: identification of the complete kindred and evidence of a dominant generic trammission. Am J Hum Genet. 1985;37:1083-1097.
15. milano apoprotein with plasma lipid and lipoprotein patterns. Atherosclerosis. 1988;58:159-174.
16. Gualandri V, Orsini GB, Cerrone A, Franceshini G, Sirtori CR. Familial association of lipids and lipoproteins in a highly consanguinous population: the Limone Sul Garda study. Metabolism. 1984;34:212-221.
17. Ameli S. Hultgardh-Nilsson A, Cercek B, Shah PK, Forrester JS, Ageland H, Nilsson J. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 1994;90:1935-1941.
18. Soma MR, Donetti E, Parolini C, Sirtori CR, Fumagalli R, Franceschini G. Recombinant apolipoprotein A-I Milano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits, Circ Res. 1995; 76:405-411.
19. Qiau JH, Xie PZ, Fishbein MC, Kreuzer J, Drake TA, Deiner LL, Lusis AJ. Pathology of atheromatous lesions in inbred and genetically engineered mice. Arterioscler Thromb Vasc Biol. 1994;14:1480-1497.
20. Zhang HS, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468-471.
21. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JC, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E deficient mice created by homologous recombination. Cell. 1972;71:343-353.
22. Heider JG, Boyett RL. Picomole determination of free and total cholesterol in cells in culture. J Lipid Res. 1978;19:514-518.
23. Karpe F, Hamsten A. Determination of apolipoprotein B-48 and B-100 in triglyceride rich lipoproteins by analytical SDS-PAGE. J Lipid Res. 1994; 35:1311-1317.
24. de la Liera Moya M, Atger V, Paul JL, Fournier N, Moatti N, Giral P, Friday KE, Rothblat G. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux: relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb Vasc Biol. 1994;14:1056-1065.
25. Kunitake ST, Jams MR, Hamilton RL, Kane JP. Binding of transition metals by apolipoprotein A-I containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc Natl Acad Sci U S A. 1992;89:6993-6997.
26. Parthasarathy S, Barnett J. Fong LG, High density lipoprotem inhibits the oxidative modification of loss-density lipoprotein. Biochem Biophys Acta. 1990;1044:275-283.
27. Franceschini G, Maderna P, Sirtori CR. Reverse cholesterol transport: physiology and pharmacology. Atherosclerosis. 1991;88:99-107.
28. Nawab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM. The Yin and Yang of oxidation in the development of the fatty streak. Artrioscler Thromb Vasc Biol. 1996;16:831-842.
29. Matsuda Y, Hirata K, Inoue N, Suematsu M, Kawashima S, Akita H. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxjtion. Circ Res. 1993; 72:1103-1109.
30. Frostegard J, Wu R, Giscombe R, Holm G, Lefvert AK, Nilsson J. Introduction of T cell activation by oxidized low density lipoprotein. Arteriosler Thromb. 1992;12:461-467.
31. Mackncss MI, Abbot C, Arrol S, Durrington PN. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting; low-density lipoprotein oxidation. Biochem J. 1992;294:829-834.
32. Bowry V, Stanley K, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A. 1992;89:10316-10320.
33. Hamilton KK, Zhao J, Sims PJ. Interactions between apolipoproteins A-1 and A-11 and the membrane attack complex of complement: affinity of the apoproteins for polymeric C9. J Biol Chem. 1993;268:3632-3638.
34. Saku K, Ahmad M, Glass-Greenwalt P, Kashyap M. Activation of fibrinolysis by apolioproteins of high density lipoproteins in man. Thromb Res. 1985;39:1-8.
35. Atger VM, de la Liera Moya M, Paul JL, Stoudt GW, Rodrigueza WV, Phillips MC, Rothblat GH. Cyclodextrins as catalysts for the removal of cholesterol from macrophage foam cells. J Clin Invest. 1997;99:773-780.
36. Franceschin G, Vecchio G, Gianfranceschi G, Magni D, Sirtori CR. Apolipoprotein A-1 Milano: accelerated binding and dissociation from lipids of a human apolipoprotein variant. J Biol Chem. 1985;260:16321-16325.
37. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518-520.
38. Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 387:414-417.
39. Ji Y, Jian B, Wang N, Sun Y, de la Liera Moya M, Phillips MC, Rothblat GH, Swaney JB, Tall AR, Scavenger receptor BI promotes high density lipoprotein mediated cholesterol efflux. J Biol Chem. 1997;272:20982-20985.
40. Palinski W, Ord VA, Plump AL, Breslow JL, Steinberg D, Witzum JL. Apo-E-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high titres of autoantibodies to malondialdehyde-lysine in serum. Arteriosler Thromb. 1994;14:605-616.
41. Aviram M, Maor I, Keidar S, Hayek T, Oiknine J, Mar-El Y, Adler Z, Kertzman V, Milo S. Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated. Biochem Biophys Res Commun. 1995;216:501-513.
42. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AL. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells, Proc Natl Acad Sci U S A. 1990;87:5134-5138.
43. Frostegard J, Nilsson J, Haegontrand A, Hamsten A, Wigzell H, Cidlund M. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U 937. Proc Natl Acad Sci U S A. 1990;87:904-908.
44. Zwijsen RML, Japenga SC, Heijen AMP, van den Bos RC, Koeman JH. Induction of platelet derived growth factor chain A gene expression in human smooth muscle cells by oxidized low density lipoprotein. Biochem Biophys Res Commun. 1992;186:1410-1416.
45. Stiko-Rahm A, Hultgardh-Nilsson A, Rengstrom J, Hamsten A, Nilsson J. Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human arterial smooth muscle cells. Arteriosler Thromb. 1992;12:1099-1109.
46. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks F, Hennekens C. A prospective study of triglyceride level, low density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882-886.
47. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein panicles with the incidence of coronary artery disease in men and woman. JAMA. 1996;276:875-881.
48. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762-2770.
49. Superko HR. Beyond LDL choloterol reduction. Circulation. 1996;94: 2351-2354.
50. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR. Lupien PJ, Despres JP. Small dense low density lipoprotein particls as a predictor of the risk of ischemic heart disease in men. Circulation. 1997;95:69-75.